

The background of the top half of the page is a dark purple gradient with large, overlapping circular shapes in shades of purple and teal. On the right side, there is a circular inset image showing a night scene of palm trees and city lights reflected in water. Overlaid on this image is a white line-art graphic of a recycling symbol (three chasing arrows forming a triangle) and a series of concentric circles.

ASH 2025

67th ASH Annual Meeting and Exposition

December 6–9, 2025
Orlando, United States



TOP ABSTRACTS

To help navigate the exciting content being presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, the ALL Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in ALL.

ASH 2025: Top abstracts in ALL

December 6–9, 2025

Oral presentations: Saturday, December 6

| Abstract | Title | Presenter | Time (EST) |
|-----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|-------------|
| 31 View | Genomic determinants of treatment outcome and identification of a new genomic subset of adult acute lymphoblastic leukemia from the ECOG-ACRIN E1910 randomized phase III trial | Xiaoming Zhong | 09:30–09:45 |
| 33 View | Impact of chimeric antigen receptor (CAR) product cell phenotypes on clinical outcomes following treatment with obecabtagene autoleucel (obe-cel) | Benjamin Simpson | 10:00–10:15 |
| 35 View | Chemotherapy selects for myeloid subclones in multiple subtypes of B-cell acute lymphoblastic leukemia | Fatemeh Alikarami | 10:30–10:45 |

Oral presentations: Sunday, December 07

| Abstract | Title | Presenter | Time (EST) |
|------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|-------------|
| 439 View | First results of the phase III GIMEMA ALL2820 trial comparing ponatinib plus blinatumomab to imatinib and chemotherapy for newly diagnosed adult Ph+ acute lymphoblastic leukemia patients | Sabina Chiaretti | 09:30–09:45 |
| 440 View | Randomized comparison of ponatinib versus imatinib in combination with chemotherapy in patients 55 years of age and older with newly diagnosed Ph+ ALL: Molecular response and initial outcome analysis of the EWALL PH03 Study | Yosr Hicheri | 09:45–10:00 |
| 441 View | Primary efficacy analysis of phase II study investigating tyrosine kinase inhibitor (TKI) and inotuzumab ozogamicin-based therapy for newly diagnosed Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL) | Anand Patel | 10:00–10:15 |
| 442 View | Single CAR-T infusion during front-line consolidation induces deep and sustained remission in newly diagnosed adult Ph+ B-ALL: A prospective phase 2 study | Runxia Gu | 10:15–10:30 |
| 443 View | CD19-CAR T cell therapy as a definitive consolidation in older adults with B-ALL in CR1 is safe and induces durable MRD- remission | Ibrahim Aldoss | 10:30–10:45 |
| 444 View | Inotuzumab ozogamicin then blinatumomab for older adults with newly diagnosed, Ph-negative, CD22-positive, B-cell acute lymphoblastic leukemia: Extended follow-up of alliance for clinical trials in oncology A041703 Cohort 1 reveals durable remission and survival | Matthew Wieduwilt | 10:45–11:00 |
| 548 View | Outcomes after relapse for adolescent and young adult patients with ALL: Results from the Children's oncology group | Jordyn Griffin | 12:15–12:30 |
| 643 View | Blinatumomab consolidation in high-risk Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia in adults: Final report of the GRAALL-2014/B-QUEST study | Nicolas Boissel | 16:30–16:45 |

| | | | |
|---------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|-------------|
| 644 View | Outcome of children and adolescents with newly diagnosed T-cell acute lymphoblastic leukemia: Results of DFCI ALL consortium protocol 16-001 | Melissa Burns | 16:45–17:00 |
| 645 View | Venetoclax plus inotuzumab ozogamicin for relapsed and refractory ALL: Results of a phase I trial | Marlise Luskin | 17:00–17:15 |
| 647 View | Updated results from the Phase 1b/2 study of MK-1045, a novel CD19xCD3 T-cell engager, in adult participants with relapsed or refractory B-cell acute lymphoblastic leukemia | Ying Wang | 17:30–17:45 |

Oral presentations: Monday, December 08

| Abstract | Title | Presenter | Time (EST) |
|---------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|-------------|
| 757 View | Outcomes in children with NCI standard-risk B-acute lymphoblastic leukemia treated with intensified post-induction therapy: Results from Children's Oncology Group studies AALL0932 and AALL1131 | Ruth Wang'onde | 10:30–10:45 |
| 758 View | Blinatumomab mitigates the impact of traditional adverse prognosticators among children with standard risk B-acute lymphoblastic leukemia: Updated results of the Children's Oncology Group (COG) Trial AALL1731 | Sumit Gupta | 10:45–11:00 |
| 811 View | Phase 1 evaluation of the safety and efficacy of rapcabtagene autoleucl (YTB323) in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) | Pere Barba | 10:30–10:45 |
| 813 View | BAFFR-CAR T cells (PMB-CT01) show promising safety and anti-leukemia efficacy in relapsed/refractory B-cell ALL patients after CD19-targeted therapy failure, including CD19-negative disease | Ibrahim Aldoss | 11:00–11:15 |

Posters

| Abstract | Title | Presenter | Date and time (EST) |
|----------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|-----------------------------------|
| 1549 View | Impact of therapy delays on outcomes in adults with BCR::ABL1 negative B-lineage acute lymphoblastic leukemia (ALL) in the ECOG-ACRIN E1910 trial randomized to conventional chemotherapy +/- blinatumomab | Bhavana Bhatnagar | Saturday, December 6, 17:30–19:30 |
| 1561 View | Front-line consolidation with CAR-T therapy in newly diagnosed adult Ph-negative B-acute lymphoblastic leukemia: Results from a prospective, phase 2 study | Shaowei Qiu | Saturday, December 6, 17:30–19:30 |
| 1574 View | Results of POLARIS-1, a global phase 3 study (Part A): Olverembatinib combined with low-intensity chemotherapy in patients with newly diagnosed (ND) Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) | Suning Chen | Saturday, December 6, 17:30–19:30 |

| | | | |
|----------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------|-----------------------------------|
| 1576 View | Blinatumomab versus high-dose chemotherapy in the first-line therapy of high-risk childhood B-cell acute lymphoblastic leukemia: The results of a Phase 3 trial of the cALL-pol consortium in Poland | Wojciech Michal Mlynarski | Saturday, December 6, 17:30–19:30 |
| 3340 View | Outcome after relapse in older patients with Philadelphia chromosome–negative B-cell ALL treated with inotuzumab ozogamicin and low-dose chemotherapy in first-line therapy: A GRAALL study | Perrine Moyer | Sunday, December 7, 18:00–20:00 |
| 3342 View | First promising results in younger adult patients (<65 yrs) with newly diagnosed Ph/BCR::ABL positive ALL treated within the randomized GMALL evolve trial | Fabian Lang | Sunday, December 7, 18:00–20:00 |
| 3345 View | Safety and efficacy of surovatamig (AZD0486) in adolescent and adult patients with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL): Updated results from the Phase 1/2 SYRUS study | Ibrahim Aldoss | Sunday, December 7, 18:00–20:00 |
| 3356 View | Ibrutinib plus blinatumomab in relapsed/refractory B-cell acute lymphoblastic leukemia: Results of a phase 2 study | Brian Jonas | Sunday, December 7, 18:00–20:00 |
| 3373 View | Impact of IKZFplus status and ABL1 kinase domain mutations in patients with newly diagnosed Philadelphia-chromosome positive acute lymphoblastic leukemia receiving imatinib and chemotherapy followed by allogeneic SCT within GMALL07/03 | Heike Pfeifer | Sunday, December 7, 18:00–20:00 |
| 5117 View | Efficacy of single-agent subcutaneous blinatumomab in adults with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL): Results from a phase 1/2 dose expansion study with extended follow-up | Elias Jabbour | Monday, December 8, 18:00–20:00 |
| 5121 View | Combination of genetics at baseline and clearance of MRD to assign the post-remission treatment of patients with Philadelphia-negative acute lymphoblastic leukemia. FINAL results of PETHEMA LAL19 trial | Anna Torrent | Monday, December 8, 18:00–20:00 |
| 5124 View | Outcome of adult B-precursor acute lymphoblastic leukemia (ALL) treated with blinatumomab in addition to chemotherapy independent of MRD: First results from the national GMALL registry | Nicola Gökbüget | Monday, December 8, 18:00–20:00 |



#ASH25

Follow us on X to keep up to date
with the latest from the congress

@ALL_Hub_



Brought to you by

